![](/img/cover-not-exists.png)
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
Kris, M.G, Herbst, R, Rischin, D, LoRusso, P, Baselga, J, Hammond, L, Feyereislova, A, Ochs, J, Averbuch, SVolume:
29
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(00)80233-0
Date:
September, 2000
File:
PDF, 111 KB
english, 2000